An introduction to clinical research [EN]

00:05:10
https://www.youtube.com/watch?v=kOVryugeUco

概要

TLDRThis video details a historical clinical trial in 1747 that identified effective treatments for scurvy, emphasizing the ongoing need for rigorous clinical trials today. It outlines key elements of clinical trials such as the formal approval process, the importance of randomization for fair comparison, and the role of blinding to reduce bias. The discussion includes potential pitfalls, such as the improper use of placebos and the necessity of including diverse patient demographics. The ultimate aim of clinical trials is not only to determine if a new treatment is effective but to ensure it genuinely improves health outcomes for patients, supported by robust evidence and transparency in research practices.

収穫

  • 📅 Historical Trial: Conducted in 1747 to test scurvy treatments.
  • 🍊 Effective Treatment: Oranges and lemons helped sailors recover from scurvy.
  • ⚖️ Ethical Approval: Protocols must be approved by independent ethics committees.
  • 🎲 Randomization: Patients must be randomly allocated to treatment and control groups.
  • 👁️‍🗨️ Blinding: Patients and doctors may not know who receives the treatment to prevent bias.
  • 🔄 Replication Required: Results should be confirmed in independent trials.
  • 📊 Evaluating Effectiveness: Treatments must do more than just show effectiveness; they must improve patient health.
  • 🚫 Issues with Placebos: Placebos shouldn't replace available effective treatments.
  • 🧑‍🤝‍🧑 Diverse Inclusion: Trials should include children, elderly, and minorities for effective treatment evaluation.
  • 🌍 Support from EU: Encouragement for transparency and organizational improvements in clinical research.

タイムライン

  • 00:00:00 - 00:05:10

    The clinical trial story begins in 1747 on a British Royal Navy ship where a doctor tested various treatments for scurvy, ultimately discovering that oranges and lemons were effective; this foundational experiment establishes the necessity of clinical trials for resolving treatment uncertainties. Subsequent trials require formal approval of protocols by independent ethics committees to prevent conflicts of interest, random assignment of patients to treatment and control groups to ensure comparability, and double blinding to eliminate bias. Results must be analyzed by unbiased researchers and replicated in independent trials to verify findings. Furthermore, the evaluation of new treatments must assess their effectiveness in improving patient health while ensuring that they do not compromise safety; the inclusion of diverse patient groups in trials is essential to obtain relevant results. A focus on actual clinical benefits rather than just treatment equivalence is critical for patient assurance. Healthcare decisions should be based on robust research to enhance public health, and organizations like the European Union can enhance clinical trial organization and transparency.

マインドマップ

ビデオQ&A

  • What year was the clinical trial for scurvy conducted?

    The clinical trial took place in 1747.

  • What was the treatment that proved effective against scurvy?

    Oranges and lemons were found to be effective.

  • What is randomization in a clinical trial?

    Randomization is the process of allocating patients to treatment and control groups at random.

  • Why is blinding used in clinical trials?

    Blinding prevents patients' and doctors' expectations from influencing the results.

  • What must be evaluated besides effectiveness in clinical trials?

    The benefits and risks of a new treatment must be carefully evaluated.

  • What is the importance of independent ethics committees?

    They ensure that the trial protocols are approved without conflicts of interest from researchers.

  • What group should a control group receive if effective treatments are available?

    The control group should receive the best available treatment.

  • What is the goal in designing a new treatment trial?

    To determine if the new treatment is actually better than existing treatments.

  • Why are diverse patient groups important in trials?

    To ensure that the treatment is intended for all populations and not exclude certain demographics.

  • What role does the European Union play in clinical research?

    The EU helps support better organization and transparency in clinical trials.

ビデオをもっと見る

AIを活用したYouTubeの無料動画要約に即アクセス！
字幕
en
オートスクロール:
  • 00:00:13
    this is the story of a clinical trial
  • 00:00:16
    that took place in 1747 on board a
  • 00:00:18
    british royal navy ship
  • 00:00:21
    to test which was the best way to treat
  • 00:00:23
    scurvy the ship's doctor gave six
  • 00:00:25
    different treatments that were
  • 00:00:26
    recommended at the time to pairs of
  • 00:00:29
    sailors
  • 00:00:33
    one of these treatments was oranges and
  • 00:00:35
    lemons
  • 00:00:36
    the two sailors who were given oranges
  • 00:00:37
    and lemons recovered
  • 00:00:39
    this trial resolved the uncertainty and
  • 00:00:41
    revealed which treatment was effective
  • 00:00:43
    since 1747 things have changed of course
  • 00:00:46
    but even now as in those days the best
  • 00:00:49
    way to address uncertainty about the
  • 00:00:51
    benefits and drawbacks of treatments is
  • 00:00:53
    to do a clinical trial
  • 00:00:57
    clinical trial first point
  • 00:00:59
    the plan of what will be done in a
  • 00:01:01
    clinical trial the protocol must be
  • 00:01:03
    formally approved not by the researchers
  • 00:01:05
    who propose it since they may have a
  • 00:01:07
    conflict of interest but by an ethics
  • 00:01:09
    committee
  • 00:01:10
    with independent experts and
  • 00:01:12
    representatives of citizens
  • 00:01:15
    second point
  • 00:01:17
    patients must be divided into groups
  • 00:01:20
    patients in one group receive the
  • 00:01:22
    treatment being tested patients in the
  • 00:01:24
    control group do not
  • 00:01:27
    in some cases the control group will
  • 00:01:30
    receive a placebo
  • 00:01:32
    and inactive preparation that is
  • 00:01:34
    otherwise identical to the experimental
  • 00:01:36
    treatment
  • 00:01:37
    however when there is already a proven
  • 00:01:40
    effective treatment patients in the
  • 00:01:41
    control group should receive the best
  • 00:01:43
    treatment available
  • 00:01:47
    patients are allocated to the groups at
  • 00:01:49
    random for example by drawing lots
  • 00:01:51
    this is called randomization and it
  • 00:01:54
    helps form groups that are similar so
  • 00:01:56
    that when their results are compared at
  • 00:01:57
    the end differences are due to the
  • 00:01:59
    interventions given and not to
  • 00:02:00
    pre-existing differences third point
  • 00:02:04
    in some trials patients do not know if
  • 00:02:06
    they're taking the treatment or the
  • 00:02:08
    placebo this is called blinding and
  • 00:02:10
    stops their expectations influencing the
  • 00:02:12
    results it is also helpful if the
  • 00:02:14
    doctors do not know who is in the
  • 00:02:16
    treatment or control group as this also
  • 00:02:18
    prevents both deliberate and
  • 00:02:19
    unintentional bias this is called double
  • 00:02:22
    blinding
  • 00:02:24
    fourth point
  • 00:02:27
    at the end of a trial
  • 00:02:28
    the results must be analyzed by unbiased
  • 00:02:31
    researchers who do not have a vested
  • 00:02:33
    interest in the findings
  • 00:02:38
    fifth point
  • 00:02:39
    a double-blind clinical trial must be
  • 00:02:41
    replicated in other independent trials
  • 00:02:46
    sixth point
  • 00:02:48
    it's not enough that the new treatment
  • 00:02:50
    is shown to be more effective than the
  • 00:02:52
    control
  • 00:02:54
    it must really improve patients health
  • 00:02:57
    so its benefits and risks must be
  • 00:03:00
    carefully evaluated
  • 00:03:03
    to make sure that the pros outweigh any
  • 00:03:05
    cons
  • 00:03:08
    pitfalls and traps
  • 00:03:11
    placebos should not be used when there
  • 00:03:13
    are other effective treatments already
  • 00:03:15
    available
  • 00:03:16
    the comparison should be made with the
  • 00:03:17
    best treatment available
  • 00:03:20
    so that the research results can be
  • 00:03:21
    confidently used to guide practice a
  • 00:03:24
    trial must include patients for whom the
  • 00:03:26
    treatment is intended children elderly
  • 00:03:28
    people ethnic minorities and women are
  • 00:03:31
    too frequently excluded from research
  • 00:03:34
    pitfalls can arise in evaluating if a
  • 00:03:36
    treatment is effective
  • 00:03:38
    for example although high levels of
  • 00:03:40
    cholesterol are a risk factor for
  • 00:03:42
    myocardial infarction a new treatment
  • 00:03:44
    aimed at reducing cholesterol cannot be
  • 00:03:46
    considered effective in preventing
  • 00:03:48
    myocardial infarction unless it reduces
  • 00:03:51
    mortality simply reducing cholesterol is
  • 00:03:53
    not enough
  • 00:03:55
    our treatment must be evaluated for its
  • 00:03:57
    ability to improve outcomes that are
  • 00:03:59
    important to patients
  • 00:04:02
    there may be shortcomings in the design
  • 00:04:03
    of clinical trials
  • 00:04:06
    the aim is not just to decide whether a
  • 00:04:08
    new treatment is as effective as the
  • 00:04:09
    current standard treatment
  • 00:04:12
    clinical trials must be designed to show
  • 00:04:14
    whether a proposed new treatment is
  • 00:04:16
    better than an existing treatment
  • 00:04:18
    patients want to know whether a new
  • 00:04:20
    treatment is actually better not just
  • 00:04:22
    the same or simply no worse the health
  • 00:04:24
    of everyone can be protected and
  • 00:04:26
    promoted by healthcare decisions that
  • 00:04:28
    are informed by high quality health
  • 00:04:30
    research and clinical trials the
  • 00:04:32
    european union which sponsors clinical
  • 00:04:35
    research on treatments of interest to
  • 00:04:37
    patients and the public can support
  • 00:04:40
    better organization transparency and
  • 00:04:43
    independence of clinical trials
  • 00:05:09
    you
タグ
  • clinical trial
  • scurvy
  • randomization
  • blinding
  • ethics committee
  • placebo
  • treatment effectiveness
  • patient health
  • health research
  • European Union